



Date: 02/11/2021

To,
The Manager
Listing Compliance Department,
BSE Limited (Bombay Stock Exchange Limited),
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir/Madam,

Ref : Script Id "BAJAJHCARE", Script Code "539872".

Sub : Outcome of Board Meeting & submission of Unaudited Financial Results for the quarter/
Half year ended September 30, 2021.

The Board of Directors at its Meeting held today has inter alia:

- Approved the unaudited Financial Statements for the quarter / half year ended September 30, 2021, as recommended by the Audit Committee; and

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, we enclose herewith the following:

- (i) Unaudited Financial Results for the quarter / half year ended September 30, 2021 along with limited review report;

The above information is also available on the Company's website at www.bajajhealth.com. This is for your information and records.

We wish to inform you that Board Meeting commenced today at 04.00 p.m. and concluded at 5.25 p.m.


Kindly take the same on record.

Thanking you,

Yours faithfully,

For and on behalf of Board of Directors
of Bajaj Healthcare Limited

Mr. Aakashkumar Keshari
Company Secretary



BAJAJ HEALTHCARE LIMITED

Registered Office : Corp. Off.: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A/1, Road No. 23, Above ICICI Bank, Wagle Ind. Estate, Thane(W)-400604.

• Tel. : +91 22 6617 7400 - 499 • Fax : +91 22 66177458 • Website : www.bajajhealth.com

CIN NO.: L99999MH1993PLC072892

Chaturvedi & Agrawal

Chartered Accountants

Independent Auditor's Review Report on the Quarter and Half Year Ended September 30, 2021
Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Bajaj Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Bajaj Healthcare Limited (the "Company") for the quarter and Half Year ended September 30, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations).
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Chaturvedi & Agrawal
Chartered Accountants
FRN: 101717W



Rasik Chaturvedi
Partner

M. No.: 039524

UDIN: 21039524AAAABK6329



Date: November 02, 2021
Place: Thane



BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30th SEPTEMBER, 2021


(Rs. In Lakhs Except for Earnings Per Share)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from operations	15,091.25	18,568.87	20,663.47	33,660.13	34,646.79	65,698.38
II. Other Income	11.84	67.95	209.49	79.79	299.67	691.26
III. Total Revenue (I+II)	15,103.09	18,636.83	20,872.96	33,739.92	34,946.45	66,389.64
IV. Expenses						
(a) Cost of materials consumed (Including Other Direct Expenses)	11,498.42	15,444.24	15,423.60	26,942.66	25,811.99	46,342.49
(b) Changes in Inventories of Finished Good	(699.72)	(1,992.56)	191.66	(2,692.28)	(184.02)	70.18
(c) Employee benefits expense	929.08	964.34	980.37	1,893.42	1,779.10	3,454.87
(d) Finance Costs	249.96	279.33	217.18	529.29	422.00	829.60
(d) Depreciation and amortisation expense	440.74	413.07	397.54	853.81	774.01	1,612.42
(e) Other expenses	466.93	803.05	836.97	1,269.98	1,474.27	2,198.12
Total Expenses	12,885.41	15,911.47	18,047.32	28,796.89	30,077.35	54,507.67
V. Profit Before Tax	2,217.68	2,725.36	2,825.64	4,943.03	4,869.10	11,881.97
VI. Tax Expense						
(a) Current tax	454.00	814.00	826.60	1,268.00	1,400.00	3,497.41
(b) Earlier Years	2.13	-0.09	(12.63)	2.04	-71.73	23.73
(c) Deferred Tax	36.40	-10.26	-	26.13	-	49.93
Total Tax Expenses	492.53	803.64	813.97	1,296.17	1,328.27	3,571.07
VII. Profit (Loss) for the Period	1,725.15	1,921.71	2,011.67	3,646.86	3,540.83	8,310.89
VIII. Other comprehensive Income						
(i) Items that will not be reclassified to profit or loss ^a	-	-	-	-	-	(30.46)
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	8.87
(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Comprehensive Income for the Period	1,725.15	1,921.71	2,011.67	3,646.86	3,540.83	8,289.31
IX. Paid-up Equity Share Capital (Face Value Rs. 5/-)	1,379.92	1,379.92	1,379.92	1,379.92	1,379.92	1,379.92
X. Other Equity excluding Revaluation Reserve	-	-	-	-	-	24,444.83
XI. EPS (Not Annualised)						
(a) Basic (in Rs.)	6.25	6.96	7.29	13.21	12.83	30.11
(b) Diluted (in Rs.)	6.25	6.96	7.29	13.21	12.83	30.11
Dividend Declared during the Year:						
Interim Dividend (Per Share)	-	-	-	-	-	1.25
Special Dividend (Per Share)	-	-	-	-	-	1.00
Final Dividend (Per Share)	-	-	-	-	-	0.50
Total Dividend (Per Share)	-	-	-	-	-	2.75
Cumulative Dividend Percentage	-	-	-	-	-	27.50%

Note :

- a) The above Financial Results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on November 2, 2021
- b) The financial results for the Quarter and Half Year Ended September 30, 2021 have been subjected to limited review by the statutory auditors of the Company.
- c) The Statement as per IND AS - 108 on segment reporting is given as Annexure-A.
- d) Figures of previous period have been regrouped/reclassified, wherever necessary, to make them comparable and to conform with current period classification.
- e) Cash Flow Statement is given as Annexure B.
- f) Pursuant to the approval of the shareholders by way of Postal Ballot on September 17, 2021, Equity Share of Rs. 10/- each fully paid up was sub divided into 2 Equity Shares of Rs. 5/- each fully paid up, with effect from the record date September 29, 2021. Consequently, the basic and diluted earnings per share have been adjusted retrospectively for all the periods presented in the Standalone Financial Results of the Company on the basis of the new number of equity shares in accordance with the provisions of applicable Ind AS.
- g) Cumulative Dividend Percentage is Calculated based on Face Value prevalent at the time of declaration of Dividend i.e. Rs. 10/- per Equity Share. The Corresponding effective Cumulative Dividend percentage pursuant to Split of the Equity Shares of the Company is 55% on face value of Rs. 5/- per Equity Share.

By Order of the Board
For Bajaj Healthcare Limited


Mr. Sajankumar R Bajaj
D.No.: 00225950
Chairman and Managing Director

Date: 02nd November 2021
Place: Thane

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

STATEMENT OF ASSETS & LIABILITIES AS AT 30th SEPTEMBER 2021

(Rs in Lakhs)

Particulars	As at	As at
	30.09.2021	31.03.2021
	(Unaudited)	(Audited)
ASSETS		
Non-current assets		
(a) Property Plant & Equipment	22,642.74	20,812.77
(b) Capital work-in-progress	5,559.02	5,704.75
(c) Financial Assets		
(i) Long Term Investments	0.31	0.31
(ii) Other Financial assets	256.31	212.04
Current assets		
(a) Inventories	15,766.39	9,711.03
(b) Financial Assets		
(i) Trade receivables	14,639.46	9,888.28
(ii) Cash and cash equivalents	180.45	1,424.11
(iii) Other Financial assets	802.15	66.33
Other Current assets	5,815.49	4,743.56
TOTAL ASSETS	65,662.32	52,563.17
EQUITY AND LIABILITIES		
Equity		
(a) Share Capital	1,379.92	1,379.92
(b) Other Equity	28,107.99	24,461.13
Sub - Total - Equity	29,487.91	25,841.05
Liabilities		
Non-Current Liabilities		
Financial Liabilities		
(a) Borrowings	7,628.75	7,971.33
Deffered Tax Liabilities	241.53	215.40
Long-term Provisions	280.13	278.06
Current Liabilities		
Financial Liabilities		
(a) Trade payables	10,648.23	6,895.37
(b) Borrowings	13,556.47	8,846.55
(c) Other Financial liabilities	2,898.75	2,348.33
Other Current Liabilities	784.84	149.29
Provisions	17.79	17.79
Current Tax Liabilities	117.91	-
TOTAL - EQUITY AND LIABILITIES	65,662.32	52,563.17

By Order of the Board
For Bajaj Healthcare Limited



Mr. Sajankumar R Bajaj
D.No.: 00225950
Chairman and Managing Director

Date: 02nd November 2021
Place: Thane

BAJAJ HEALTHCARE LTD.
Cash Flow Statement for the Half Year ended 30th September 2021
(CIN No. : L99999MH1993PLC072892)

Amt (Rs. In Lakhs)

Sr No	Particulars	Half Year ended on 30th Sept 2021		Half Year ended on 30th Sept 2020	
A	<u>CASH FLOW FROM OPERATING ACTIVITIES</u>		4,943.03		4,869.10
	Net Profit Before Tax				
	Adjustments for:				
	Depreciation	853.81		774.01	
	(Profit)/loss on sale of Assets	-		(0.48)	
	Interest & Finance Charges	529.29		422.00	
	Interest on FD	(7.54)		(2.72)	
	Provision for Employee Benefits & Leave Enchashment	-		66.37	
	ECL Provision	16.92		(74.94)	
	Dividend Income	-	1,392.48	-	1,184.22
	Operating Profit before Working Capital Changes		6,335.51		6,053.32
	Adjustments for:				
	(Increase)/Decrease in Other current assets	(1,852.02)		(287.86)	
	(Increase)/Decrease In Sundry Debtors	(4,768.11)		(1,083.38)	
	(Increase)/Decrease In Inventories	(6,055.36)		(3,321.46)	
	Increase /(Decrease) in non current and current liabilities	4,908.51		1,570.15	
	Cash generated from operations		(7,766.98)		(3,122.55)
	Income Tax Paid		(1,431.46)		2,930.77
	Net Cash flow from Operating activities		(1,152.13)		(922.56)
			(2,583.59)		2,008.21
B	<u>CASH FLOW FROM INVESTING ACTIVITIES</u>				
	Purchase of Fixed Assets	(2,683.78)		(2,412.11)	
	Increase/(Decrease) in Capital Wip	145.72		(1,939.20)	
	Sale Of Fixed Assets			2.87	
	Interest on FD	7.54		2.72	
	Payment to Gratuity Fund	32.40		(4.17)	
	Net Cash used in Investing activities		(2,498.11)		(4,349.89)
C	<u>CASH FLOW FROM FINANCING ACTIVITIES</u>				
	Increase /(Decrease) From Long Term Borrowing	(888.93)		1,487.17	
	Increase /(Decrease) Of Unsecured Long Term Borrowing	546.35		(60.43)	
	Increase /(Decrease) Of Short Term Borrowing From Bank	4,709.92		1,483.09	
	Increase /(Decrease) Of Borrowing From Director & Inter corporates	-		(7.25)	
	Interest paid	(529.29)		(422.00)	
	Net Cash used in financing activities		3,838.05		2,480.57
	Net increase in Cash & Cash Equivalents (A+B+C)		(1,243.66)		138.89
	Opening balance of Cash and Cash equivalents as on April 1		1,424.11		415.85
	Closing balance of Cash and Cash equivalents as on September 30		180.45		554.74

For and on behalf of the Board
of Bajaj Healthcare Ltd


S K R Bajaj
Chairman and Managing
Director
DIN :00225950

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

REPORT ON SEGMENT RESULTS FOR QUARTER AND HALF YEAR ENDED ON 30th September, 2021

Annexure : A

(Rs. In Lakhs)

Sr No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A	Segment Revenue (Excluding Intersegment Revenue)						
	Bulk Drugs	13741.05	13528.72	17442.86	27269.77	30011.13	59336.46
	Formulations	1350.20	5040.16	3220.60	6390.36	4635.66	6361.92
	Total	15,091.25	18,568.87	20,663.47	33,660.13	34,646.79	65,698.38
	InterSegment Revenue						
	Bulk Drugs	1511.41	4,422.16	1,043.69	5,933.57	1,827.15	2,586.87
	Formulations	0.00	615.12	29.66	615.12	33.20	210.83
	Total	1,511.41	5,037.28	1,073.35	6,548.68	1,860.35	2,797.69
	Gross Segment Revenue (Including Intersegment Revenue)						
	Bulk Drugs	15252.46	17950.88	18486.55	33203.34	31838.28	61923.32
Formulations	1350.20	5655.27	3250.26	7005.47	4668.86	6572.75	
Total	16,602.66	23,606.15	21,736.81	40,208.81	36,507.14	68,496.07	
B	II. Segment Results						
	Profit / (Loss) Before Tax & Finance Cost						
	Bulk Drugs	2848.54	3,495.49	3,272.53	6,344.03	6,019.13	13,924.25
	Formulations	86.03	312.25	694.14	398.28	821.19	985.43
	Total	2,934.57	3,807.74	3,966.67	6,742.31	6,840.32	14,909.68
Less : Interest	249.96	279.33	217.18	529.29	422.00	829.60	
Other Unallocable Expenditure (Net)	466.93	803.05	923.85	1,269.98	1,549.22	2,198.12	
Total Profit Before Tax	2,217.68	2,725.36	2,825.64	4,943.03	4,869.10	11,881.97	
C	I. Segment Assets						
	Bulk Drugs	60,655.53	55,247.77	39,224.93	60,655.53	39,224.93	50,063.51
	Formulations	5,006.48	4,991.22	3,042.09	5,006.48	3,042.09	2,499.35
	Others	0.31	0.31	500.31	0.31	500.31	0.31
	Total	65,662.32	60,239.29	42,767.33	65,662.32	42,767.33	52,563.17
	II. Segment Liabilities						
	Bulk Drugs	34,687.79	30,264.51	19,438.32	34,687.79	19,438.32	25,743.74
	Formulations	947.16	1,683.63	1,101.86	947.16	1,101.86	484.92
	Others	539.45	528.39	900.51	539.45	900.51	493.46
	Total	36,174.41	32,476.53	21,440.69	36,174.41	21,440.69	26,722.12
Total Capital Employed	29,487.91	27,762.76	21,326.64	29,487.91	21,326.64	25,841.05	
Total (II+III)	65,662.32	60,239.29	42,767.33	65,662.32	42,767.33	52,563.17	

By Order of the Board
For Bajaj Healthcare Limited

Mr. Sajankumar R Bajaj
D.No.: 00225950
Chairman and Managing Director

Place : Thane
Date: 02nd November 2021